Specialty Pharmacy

Ideally, these contracts help address criticism of the 340B program, improve patient outcomes, and increase compliance.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the endpoints of the phase 2 trial assessing niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Relatlimab plus nivolumab (Opdualag) shows improved progression-free survival compared with nivolumab monotherapy in patients with unresectable or metastatic melanoma.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses how patients were selected for the phase 2 trial assessing niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses how SGO shapes and guides the direction of medical researchers and health care professionals in the gynecologic oncology field.

Only 40% of patients with platinum sensitive disease are receiving a PARP inhibitor in the first-line setting.

Use of mirvetuximab soravtansine monotherapy in patients with ovarian cancer resulted in meaningful anti-tumor activity, consistent safety, and favorable tolerability.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the design of the phase 2 trial assessing niraparib in patients with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses the future of the pharmacist on the gynecologic oncology patient care team.

Black women are at an increased risk of dying from cancer of any type compared to White women, but gynecologic cancers have some of the widest survival gaps.

Hormone replacement therapy can improve quality of life without necessarily increasing the risk of recurrence.

Although poorer prognoses are common for all patients with advanced and recurrent endometrial cancers, minority populations are disproportionately affected with higher rates of mortality.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses the role of the pharmacist in gynecologic oncology patient care and treatment.

Shannon Hough, director of ClinReview and Clinical Content for McKesson, discusses the advantages of including pharmacy staff as part of the care team when payer or drug availability challenges arise.

Encorafenib in combination With anti-EGFR monoclonal antibody improves overall survival.

Olaparib (Lynparza) was found to significantly improve overall survival in patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses some key developments in the field of gynecologic oncology that will be on the agenda at the SGO 2022 annual meeting.

The median survival time of patients was 12 months compared with 7 in the control group, the analysis demonstrates.

Ramucirumab (Cyramza; Eli Lilly) is FDA-approved for 5 unique cancer indications.

Olaparib (Lynparza) approved for patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

In the third part of the series, we further explore the factors that contribute to overall happiness in a position.

Kelsey Ramsden, co-founder, president, and CEO at MindCure, discussed the potential links between sexual trauma and hypoactive sexual desire disorder in women.

Shannon Hough, director of ClinReview and Clinical Content for McKesson, discusses the growing shift to biosimilars in oncology and the impact of increased access and reduced financial burden for patients on medication adherence.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses what oncology pharmacists should understand about rucaparib when treating ovarian cancer.

Insurers, accountable care organizations, and manufacturers increasingly look for demonstrable clinical outcomes as proof for reimbursement or access to limited distribution networks.

Supplemental new drug application submitted to the FDA for the approval of darolutamide (Nubeqa) plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

A patient’s ability to pay for specialty medications will continue to be an issue because drug costs are prohibitive and add barriers to accessibility.

Phase 3 TROPiCS-02 study continues to follow patients for overall survival, a key secondary endpoint.

Epcoritamab is an investigational immunoglobulin G1-bispecific antibody being evaluated as a treatment for patients with follicular lymphoma in multiple clinical trials.